<DOC>
	<DOCNO>NCT01090323</DOCNO>
	<brief_summary>The safety , tolerability , effect liver iron concentration pharmacokinetics ICL670 study sickle cell disease patient transfusional hemosiderosis .</brief_summary>
	<brief_title>Evaluation Safety , Tolerability , Pharmacokinetics ( PK ) Effects Liver Iron Concentration ICL670 Relative Deferoxamine ( DFO ) .</brief_title>
	<detailed_description>The treatment period start patient complete core study sign informed consent . It continue 4 year . Safety parameter assess every 4 week . Eye Ear examination perform yearly basis . To investigate extent iron overload , serum ferritin , iron , transferrin monitor every four week . The Program Safety Board monitor safety ICL670 study evaluate categorize serious case report association ICL670 .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>Patients include meet follow criterion : Completion core [ Study 0109 ] Serum ferritin great equal 500 µg/L Ability comply studyrelated procedure , medication , evaluation Sexually active postmenarche female patient must use doublebarrier contraception , oral contraceptive plus barrier contraceptive , must undergo clinically document total hysterectomy and/or oophorectomy , tubal ligation postmenopausal define amenorrhea least 12 month . Written inform consent assent patient parent legal guardian . Additional inclusion criterion pediatric patient The definition term 'pediatric ' enrollment study conduct accordance local law . Parents legal guardian fully inform investigator requirement study . The pediatric patient inform accord capability language term able understand . Written inform consent obtain legal guardian patient 's behalf accordance national legislation . If capable , patient also personally sign write informed consent . Patients meet follow criterion exclude : History noncompliance medical regimens patient consider potentially unreliable and/or cooperative Serum creatinine ageappropriate upper limit normal within one week prior entry Patients ALT ≥ 500 U/L within one week prior entry Evidence chelationrelated cataract hear loss within 4 week prior baseline Pregnancy ( indicate serum βHCG pregnancy test female patient potential become pregnant ) patient breastfeed Patients treated systemic investigational drug within 4 week prior topical investigational drug within 7 day prior baseline visit Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Deferasirox</keyword>
	<keyword>ICL670A</keyword>
	<keyword>Iron chelators</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Transfusional Hemosiderosis</keyword>
</DOC>